BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 36081374)

  • 1. Feasibility of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced peritoneal surface tumors during the COVID-19 pandemic: A single-institution experience.
    Radomski SN; Florissi I; Khan H; Siddiqi A; Paneitz DC; Johnston FM; Greer JB
    J Surg Oncol; 2022 Dec; 126(8):1375-1382. PubMed ID: 36081374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?
    Strong EA; Livingston A; Gracz M; Peltier W; Tsai S; Christians K; Gamblin TC; Kersting K; Clarke CN
    J Surg Res; 2022 Oct; 278():31-38. PubMed ID: 35588572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 5. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
    Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
    Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany.
    Reese M; Eichelmann AK; Nowacki TM; Pascher A; Sporn JC
    Langenbecks Arch Surg; 2024 Apr; 409(1):113. PubMed ID: 38589714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
    Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
    World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
    Chang SC; Fingerhut A; Chen WT
    Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The robotic future of minimally invasive cytoreduction and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
    Ortega J; Orfanelli T; Levine E; Konstantinidis IT
    Chin Clin Oncol; 2023 Apr; 12(2):16. PubMed ID: 36946185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
    Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
    J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complexity of surgery and treatment burden in patients with peritoneal malignancy is not determined by addition of hyperthermic intraperitoneal chemotherapy.
    Steffens D; Ansari N; Koh C; Ahmadi N; Solomon MJ; Hogan S; Karunaratne S; Anderson T; Harvey K; McBride K; Moran B
    ANZ J Surg; 2024 Apr; 94(4):628-633. PubMed ID: 38450829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
    Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
    World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.
    Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O
    Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.